Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -7 of 7
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
Intrathecal DepoCyte and Lineage-Targeted Minimal Residual Disease-Oriented Therapy of Acute Lymphoblastic Leukemia
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Active
18 to 65
Other
NILG-ALL 10/07
NCT00795756
2.
DepoCyt Plus Temozolomide in Patients With Neoplastic Meningitis
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
18 and over
Other
2005-0135
NCT00515788
Last Modified:
11/7/2008
 
First Published:
11/20/2003
3.
Phase II Study of Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Other
BIDMC-2003P-000182
NCT00073957
Last Modified:
11/24/2008
 
First Published:
10/21/2006
4.
Phase II Study of Rituximab, Cyclophosphamide, Vincristine, Doxorubicin Hydrochloride, and High-Dose Methotrexate (R-CODOX-M) Alone or Alternating With Rituximab and Ifosfamide, Etoposide Phosphate, and High-Dose Cytarabine (IVAC) in Combination With Intrathecal CNS Prophylaxis in Patients With Newly Diagnosed, HIV-Associated Burkitt's or Atypical Burkitt's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Biomarker/Laboratory analysis, Treatment
Active
18 and over
NCI
AMC-048
AMC-048, NCT00392834
5.
Depocyte in the Treatment of CNS Relapse in Patients With Lymphoblastic Leucemia or Very Aggressive Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Other
2004-004414-17
DEPOCYLAN, NCT00388531
6.
Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-Cell Lymphoma With Neuromeningeal Invasion at Diagnosis
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 to 60
Other
R-C5R 2006
R-C5R, NCT00553943
7.
High-Dose Sequential Chemoimmunotherapy for B-Cell Lymphomas With Central Nervous System Involvement
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
19 to 65
Other, Pharmaceutical / Industry
SCNSL1
IIL-SCNSL-1, NCT00801216
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute